Scope and Claims of US Patent 8,088,368 (United States) and the US Patent Landscape for Related HCV Small-Molecule/Combination Therapy
US Drug Patent 8,088,368 is a US chemistry-and-composition patent that claims HCV-targeted small-molecule compounds defined by a multi-variable structural formula and broad pharmaceutically acceptable salts and prodrugs, plus pharmaceutical compositions that cover monotherapy and combination regimens with specified additional HCV therapeutic classes and nucleoside analogs (including ribavirin and close analogs). Based on the claim set provided, the patent’s enforceable scope is driven by (i) the breadth of its substituent definitions (V, L, M, and the variable A15/P/R′″ definitions inside the Markush structure), and (ii) whether competitor products fall within the claimed core scaffold versus only being “adjacent” analogs that avoid one or more defined subgroups.
What patents protect the chemical scaffold in US 8,088,368?
Answer: US 8,088,368 claims a core compound scaffold with variable substitution points that include benzimidazolyl (L) and a 5-membered heteroaryl ring (M) plus an additional variable A15/P/R′″ construct. The protection is primarily for specific compound structures (not just families of use), and is extended to salts and prodrugs.
How broad is the claimed compound formula (claims 1, 9, 12, 18)?
The independent compound claim is claim 1, which recites:
- A compound of a formula where:
- V is alkyl
- L is benzimidazolyl
- M is a 5-membered heteroaryl ring
- A15 is a variable substituent defined via P and R′″
- P is selected from a set (text truncated in the provided excerpt)
- R′″ is hydrogen or methyl
- The claim covers pharmaceutically acceptable salts and prodrugs
Claim 9 and claim 10 are narrower restatements that keep key variables (notably V and A15, and in claim 9 also M) while reducing other degrees of freedom.
Claim 12 and claim 18 are additional formula claims in the set you provided, again with coverage for salts and prodrugs.
What does the Markush structure imply for enforceability?
Because the claims are Markush-style, enforceability hinges on whether a competitor’s structure satisfies each defined variable slot:
- L must be benzimidazolyl: a non-benzimidazole aromatic core likely avoids literal infringement for that claim element.
- M must be a 5-membered heteroaryl ring: changing ring size (6-membered), removing heteroatoms, or using a different ring motif likely avoids literal coverage.
- V must be alkyl: if V is aryl/heteroaryl or constrained to something outside “alkyl,” that can defeat literal scope.
- R′″ must be H or methyl: substitution beyond that (ethly/tert-butyl/halogens on that position) avoids literal infringement.
- The A15/P selection is critical but your excerpt truncates the actual list of P options. The “P selected from …” clause is often where competitors successfully design around by choosing a substituent not listed.
Which product types are covered: small molecules vs prodrugs vs salts?
Answer: US 8,088,368 covers (i) the active small-molecule, (ii) pharmaceutically acceptable salts, and (iii) prodrugs. That combination usually creates an IP barrier for “evergreening” strategies using salt forms or prodrug prodrugs that are used to improve oral bioavailability, stability, or target exposure.
Claims that explicitly capture salts/prodrugs
- Claims 1, 2, 7, 8, 9, 10, 12, 18, 23 explicitly include: “or a pharmaceutically acceptable salt, or prodrug thereof.”
Practical infringement risk for generic entrants
For a generic applicant seeking Paragraph IV opportunities, the salt/prodrug coverage means:
- even if the exact free-base compound is avoided, a product that is formulated as a covered salt or prodrug can still land within the literal claim language, assuming the claimed prodrug definition is met by the competitor’s conversion chemistry.
What formulations are protected by US 8,088,368?
Answer: The patent protects pharmaceutical compositions containing the claimed compound plus carriers, and it covers combination products with specified HCV treatment agents, including nucleoside analogs.
Composition claims (claims 13, 19) and combination expansions (claims 14-15, 20-21)
- Claim 13: pharmaceutical composition with the compound (or salt/prodrug) and at least one pharmaceutically acceptable carrier.
- Claim 14: composition with at least one additional therapeutic agent.
- Claim 15: defines additional therapeutic agents as selected from:
- ribavirin analogs
- NS3 protease inhibitors
- NS5b polymerase inhibitors
- alpha-glucosidase 1 inhibitors
- hepatoprotectants
- non-nucleoside inhibitors of HCV
- other drugs for treating HCV
- Claim 16-17: adds a nucleoside analogue selected from:
- ribavirin
- viramidine
- levovirin
- an L-nucleoside
- isatoribine
- Claims 19-23: parallel composition coverage.
How broad is the “additional therapeutic agent” clause?
The “selected from the group consisting of … other drugs for treating HCV” language is expansive. It is not limited to one class. That means:
- combination regimens that include many standard-of-care classes can still fall within the claim if they are packaged together in a composition claim setting (not just a co-admin regimen, depending on how “composition comprising” is construed under the claims’ full text).
How nucleoside analogue selection increases coverage
The nucleoside analogue list captures multiple ribavirin-family and related analogs. This is a common litigation pressure point: if competitors’ marketed regimens include ribavirin or analogs, combination composition claims can be harder to design around.
What method-of-use or therapeutic-use patents are covered by this patent?
Answer: The claims you provided are not classic “method of treating” claims. They are primarily compound and composition claims. The therapeutic linkage comes through the composition including additional therapeutic agents and through the implied therapeutic context (“other drugs for treating HCV”).
Does claim 14/15 function like use coverage?
It operates as combination composition coverage: “composition comprising … and at least one additional therapeutic agent.” That is functionally close to use coverage in enforcement but remains tied to what is “comprising” within the claimed composition.
When does exclusivity end for products covered by this patent?
Answer: The excerpt does not include filing date, priority date, patent term adjustment (PTA), maintenance, or expiration. Without those items, an exclusivity or expiration calendar cannot be computed from the claim language alone.
How strong is the patent estate for the HCV compound space around US 8,088,368?
Answer: On the basis of the provided claims alone, US 8,088,368 is structurally broad:
- It covers multiple variable substituent slots (V, L, M, and A15/P/R′″).
- It includes salts and prodrugs.
- It includes compositions and combination therapies across multiple HCV drug classes plus ribavirin-family nucleosides.
This breadth typically increases litigation leverage but also increases invalidity risk if prior art discloses overlapping scaffolds with predictable variation. The actual strength relative to the prior art depends on the prosecution history and cited references, which are not present in your input.
What generic entry risks exist if a competitor files a Paragraph IV ANDA for an HCV drug?
Answer: The entry risks depend on whether the competitor’s ANDA product is:
- a covered active ingredient (free base),
- a covered salt form,
- a covered prodrug,
- or a marketed combination composition that falls within the composition claims.
If the competitor avoids the benzimidazolyl requirement (L), uses a different ring motif than the claimed 5-membered heteroaryl for M, uses substituents for R′″ beyond H/methyl, or selects an A15/P option outside the claimed P set, literal infringement becomes less likely. If the competitor instead markets a product that uses a covered scaffold in a carrier formulation with ribavirin or ribavirin analogs and other named HCV classes, the composition claims can create additional leverage for patent holders.
How does US 8,088,368 compare with other HCV small-molecule patent families?
Answer: The claim architecture you provided aligns with a typical HCV small-molecule portfolio strategy:
- Core chemical coverage via broad Markush formula claims (compound claims).
- Salt/prodrug coverage for formulation and lifecycle management.
- Composition coverage for marketed regimens.
- Combination clause that explicitly names major HCV therapy classes (NS3, NS5b, NNIs) and ribavirin-family analogs.
This makes the patent more “regimen-relevant” than single-agent-only patents.
Key Takeaways
- US 8,088,368 claims an HCV-targeted small-molecule scaffold defined by a multi-variable formula anchored on benzimidazolyl (L) and a 5-membered heteroaryl ring (M), with additional constraints including R′″ = hydrogen or methyl and a Markush A15/P selection (P list not included in your excerpt).
- The patent extends scope to pharmaceutically acceptable salts and prodrugs.
- Composition claims cover formulations using the active compound plus carriers, and combination compositions that include additional HCV therapeutics spanning NS3 protease inhibitors, NS5b polymerase inhibitors, non-nucleoside inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, ribavirin analogs, and “other drugs for treating HCV.”
- The nucleoside analogue clause lists ribavirin, viramidine, levovirin, L-nucleoside, and isatoribine, creating high relevance to ribavirin-based HCV regimens.
- Expiration/exclusivity and litigation/Orange Book status cannot be derived from the claim excerpt alone.
FAQs
1) What structural elements must an infringing compound include for US 8,088,368 claim 1?
Benzimidazolyl (L) plus a 5-membered heteroaryl (M), with R′″ limited to hydrogen or methyl, and the remaining substituents matching the Markush definitions for V and A15/P.
2) Do salts and prodrugs of the claimed compound fall within US 8,088,368?
Yes, the claims you provided repeatedly include “pharmaceutically acceptable salt, or prodrug thereof.”
3) Does US 8,088,368 cover combination therapy with ribavirin?
Yes. The composition claims explicitly cover ribavirin and ribavirin-family nucleoside analogs.
4) Can a competitor avoid infringement by changing the ring size of M?
Changing M away from a 5-membered heteroaryl motif is a direct design-around to the literal claim element “M is a 5-membered heteroaryl ring.”
5) Are NS3/NS5b inhibitors and non-nucleoside HCV drugs included in the protected combinations?
Yes. The additional therapeutic agent clause enumerates NS3 protease inhibitors, NS5b polymerase inhibitors, and non-nucleoside inhibitors of HCV.
References
No external sources were cited because the prompt provided only the claim text excerpt and did not include bibliographic data (publication date, priority, assignee, Orange Book listings, prosecution history, or litigation docket) needed for verifiable citation.
